Chloroquine-induced torsade de pointes in a COVID-19 patient

Further Publications

QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin

Heart Rhythm.

Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, Knotts R, Bar-Cohen R, Kogan E, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Stefano C, Chinitz LA, Jankelson L

doi: 10.1016/j.hrthm.2020.05.014.

Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes

Heart.

Lazzerini PE, Laghi-Pasini F, Bertolozzi I, Morozzi G, Lorenzini S, Simpatico A, Selvi E, Bacarelli MR, Finizola F, Vanni F, Lazaro D, Aromolaran A, El Sherif N, Boutjdir M, Capecchi PL

doi: 10.1136/heartjnl-2016-311079.

Further Publications

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

JAMA Cardiol.

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS

doi: 10.1001/jamacardio.

Further Publications

The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection

Circ Arrhythm Electrophysiol.

Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM

doi: 10.1161/CIRCEP.120.008662.

Further Publications

Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry

Am Heart J

Núñez-Gil IJ, Olier I, Feltes G, Viana-Llamas MC, Maroun-Eid C, Romero R, Fernández-Rozas I, Uribarri A, Becerra-Muñoz VM, Alfonso-Rodriguez E, García-Aguado M, Elola J, Castro-Mejía A, Pepe M, Garcia-Prieto JF, Gonzalez A, Ugo F, Cerrato E, Bondia E, Raposeiras S, Mendez JLJ, Espejo C, Masjuan ÁL, Marin F, López-Pais J, Abumayyaleh M, Corbi-Pascual M, Liebetrau C, Ramakrisna H, Estrada V, Macaya C, HOPE COVID-19 investigators (Cols appendix).

doi: 10.1016/j.ahj.2021.04.001

Cardiovascular Risk and Diseases

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

JAMA Cardiol.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C

doi: 10.1001/jamacardio.2020.0950.

Cardiovascular Risk and Diseases

Ramipril in High Risk Patients with COVID-19

J Am Coll Cardiol.

Amat-Santos IJ, Santos-Martinez S, López-Otero D, Nombela-Franco L, Gutiérrez-Ibanes E, Del Valle R, Muñoz-García E, Jiménez-Diaz VA, Regueiro A, González-Ferreiro R, Benito T, Sanmartin-Pena XC, Catalá P, Rodríguez-Gabella T, Delgado-Arana JR, Carrasco-Moraleja M, Ibañez B, San Román JA

doi: 10.1016/j.jacc.2020.05.040.

Thrombosis and Stroke

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

JAMA Intern Med

Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI, HEP-COVID Investigators.

doi: 10.1001/jamainternmed.2021.6203

PHARMA NEWS

Heart, Artery and Coronary Diseases

Dans l’étude de phase-III THEMIS¹, le ticagrélor (Brilique^®) diminue le risque d’évènements cardiovasculaires chez les patients atteints de maladie coronarienne et de diabète de type 2*

Communiqué de presse de AstraZeneca AG

doi: 10.1056/NEJMoa1908077.

Related content

QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin

Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection

Renin-Angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Ramipril in High Risk Patients with COVID-19

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Dans l’étude de phase-III THEMIS1, le ticagrélor (Brilique®) diminue le risque d’évènements cardiovasculaires chez les patients atteints de maladie coronarienne et de diabète de type 2*

Dans l’étude de phase-III THEMIS¹, le ticagrélor (Brilique^®) diminue le risque d’évènements cardiovasculaires chez les patients atteints de maladie coronarienne et de diabète de type 2*